All posts by medical

Cell Biology

Global Cell And Tissue Analysis Products Market with Coronavirus (Covid-19) Effect Analysis | likewise Industry is Booming Globaly with Key Players…

Cell And Tissue Analysis Products Market Global and outlook (2015 2025)

The report published onCell And Tissue Analysis Productsis a invaluable foundation of insightful data helpful for the decision-makers to form the business strategies related R&D investment, sales and growth, key trends, technological advancement, emerging market and more. The global Cell And Tissue Analysis Products market report includes key facts and figures data which helps its users to understand current scenario of the global market along with anticipated growth. The Cell And Tissue Analysis Products market report contains quantitative data such as global sales and revenue (USD Million) market size of different categories and sub categories such as regions, CAGR, market shares, revenue insights of market players, and others. The report also gives qualitative insights on the global Cell And Tissue Analysis Products market, that gives the exact outlook of the global as well as country level Cell And Tissue Analysis Products market.

Click Here To Access The Free Sample Report:http://www.marketresearchstore.com/report/global-cell-and-tissue-analysis-products-market-report-289478#RequestSample

Major Companies Profiled in the Global Cell And Tissue Analysis Products Market are: Danaher, Luminex, EMD Millipore Corporation, PARTEC, GE Healthcare, Thermo Fisher Scientific, BD, Mindray, PerkinElmer, Miltenyi Biotec

The focus of the global Cell And Tissue Analysis Products market report is to define, categorized, identify the Cell And Tissue Analysis Products market in terms of its parameter and specifications/ segments for example by product, by types, by applications, and by end-users. This study also provides highlights on market trends, market dynamics (drivers, restrains, opportunities, challenges), which are impacting the growth of Cell And Tissue Analysis Products market.

By Type the Cell And Tissue Analysis Products market is segmented into: Cell & Tissue Characterization Products, Bio specimens, Cell Separation Products

By Application the Cell And Tissue Analysis Products market is segmented into: Drug Discovery and Development, Stem Cell Research, Cell Biology, Other Research Practices

For Any Query Regarding the Cell And Tissue Analysis Products Market Report? Contact Us at:http://www.marketresearchstore.com/report/global-cell-and-tissue-analysis-products-market-report-289478#InquiryForBuying

Regions covered in this study are North America, Europe, Middle East & Africa, Latin America, and Asia Pacific. These regions are further analyzed based on the major countries in it. Countries analyzed in the scope of the report are the U.S., Canada, Germany, the UK, France, Spain, Italy, China, India, Japan, South Korea, Southeast Asia countries, Australia, Brazil, Mexico, GCC countries, South Africa, and Turkey among others.

Significant aspects of the Reports and Main Highlights:

A detailed look at the Cell And Tissue Analysis Products Industry Changing business trends in the global Cell And Tissue Analysis Products market Detailed market bifurcation analysis at different level such as type, application, end user, Regions / countries Historical and forecast size of the Cell And Tissue Analysis Products market in terms of Revenue (USD Million) Recent industry development and market trends Competitive Landscape and player positioning analysis for the Cell And Tissue Analysis Products market Key Product Offerings by Major players and business strategies adopted Niche and Potential segments (ex. types, applications, and regions/countries) anticipated to observed promising growth Key challenges faced by operating players in the market space Analysis of major risks associated with the market operations

Browse Full Research Report Now@http://www.marketresearchstore.com/report/global-cell-and-tissue-analysis-products-market-report-289478

Read more here:
Global Cell And Tissue Analysis Products Market with Coronavirus (Covid-19) Effect Analysis | likewise Industry is Booming Globaly with Key Players...

Cell Biology

Increasing Demand for Cytokines Market to Substantially Surge the Revenues Through the COVID-19 Lockdown Phase and Forecast 2019 2029 Cole Reports -…

Cytokines are the cell signaling molecules which are secreted from the different body cells. Cytokines are the proteins which play an important role of messenger between cells and regulates various physiological and metabolic activities. Cytokines regulate various inflammatory responses, stimulate blood cells production, and stimulate tissue development & maintenance. Cytokine is a large family of the small protein which includes tumors necrosis factor, interleukins, interferons, lymphokines and chemokines. Cytokines are produced by a wide range of cells includes cells like macrophages, lymphocytes, T lymphocytes, endothelial cells, mast cells, fibroblasts, stromal cells and cells. Some cytokines developed into protein therapeutics to treat bone-related disorders, anemia, cancer, infection, multiple sclerosis. Cytokine is most commonly used in the research & development activities in the field of life sciences and drug development.

Request to Sample report @ https://www.persistencemarketresearch.com/samples/30223

Increasing research and development activities expected to favour the growth of the cytokines market. As well as growing life science research funding boost up the growth of the cytokines market. Increasing prevalence of diseases such as cancer and skin disorders expected to drive the growth of the cytokines market. The growing demand for regenerative medicines impels the growth of the cytokines market. The growing demand for cytokines for wound management and cancer therapeutics expected to drive the growth of the market. Growing funding for cancer-based research influencing the growth of cytokines market. Growing cell culture-based research activities and increasing demand for cytokines in stem cell biology are major factors expected to drive the growth of the cytokines market. Growing manufacturers investments in cell culture media production expected to favour the growth of the growth factors market over the forecast period. Growing strategic acquisition and merger activities among market players is the major trend in the cytokines market. The high cost of research-based cytokines products is the major factor expected to restrain the growth of the cytokines market.

Request PMR insights on measuring the impact of COVID-19 coronavirus across industries.

The global cytokines market is segmented on basis of product type, application, end users and region:

Cytokine is the large family of cytokines includes tumour necrosis factor-TNF, interleukins (IL), interferons, chemokines and other cytokines. Interleukins (IL) is the most commonly used cytokine and have large family. IL-1 family, IL-4 family, IL-6 family, IL-10 family are mostly commonly used interleukins family in the research. Cytokines are used in various field of the research such as dermatology, cancer, orthopedics, respiratory and other fields. Cytokines are used for the research application among end users such as pharmaceutical & biotechnology companies, contract research organizations and academic & research institutes.

North America expected to dominate the global cytokines market as increasing demand for cytokines products as increasing research and development activities. Europe expected to contribute second-highest revenue share in global cytokines market as a growing number of clinical trial and drug development activities. The Asia Pacific expected to grow with the highest growth rate in the cytokines market as an increasing number of pharmaceutical manufacturers, biotechnology companies and academic institutions in the Asia Pacific region. India, South Korea & China cytokines market expected to grow with a higher growth rate as growing research and development funding from the government. The Middle East & Africa cytokines market expected to grow with the lowest growth rate due to lack of research and development activities in the region.

Request to View TOC @ https://www.persistencemarketresearch.com/toc/30223

Some of the players operating in the global cytokines market are ,

For in-depth competitive analysis, buy [emailprotected] https://www.persistencemarketresearch.com/checkout/30223

View original post here:
Increasing Demand for Cytokines Market to Substantially Surge the Revenues Through the COVID-19 Lockdown Phase and Forecast 2019 2029 Cole Reports -...

Immunology

The 3 Most Important Things to Know About AbbVie’s Q1 Update – Motley Fool

AbbVie's (NYSE:ABBV) share price has been hit pretty hard this year by the COVID-19 pandemic. But its underlying business hasn't.

The big drugmaker announced its first-quarter results before the market opened on Friday. AbbVie easily beat Wall Street's revenue and earnings estimates, delivering strong year-over-year growth on its top and bottom lines. The company also maintained its full-year 2020 adjusted earnings outlook, projecting 8.1% year-over-year growth at the midpoint of its guidance range.

All of these items are significant. But here are the three most important things to know about AbbVie's Q1 update.

Image source: Getty Images.

When Humira first began to face biosimilar competition in Europe, some might have thought the end was nigh for the world's best-selling drug. International sales for Humira plummeted throughout 2019. And international sales for the immunology drug continued to fall in the first quarter of 2020, down 14.9% year over year.

But the big picture for Humira continues to look pretty good. AbbVie reported total Q1 sales for the drug of $4.7 billion, up 5.8% year over year. This growth amounted to an extra $257 million for the company.

Although Humira continues to struggle in international markets, it's performing really well in the U.S. with sales jumping 13.7% year over year to nearly $3.7 billion. To be sure, it's only a matter of time before Humira's U.S. sales begin to sink. The drug faces biosimilar competition in the U.S. beginning in 2023. However, the longer Humira still hums along, the more time AbbVie has to get its post-Humira strategy fully into place.

That leads to the second important thing to know about AbbVie's Q1 update. The key drugs that are critical to the company's post-Humira future are gaining solid momentum.

First-quarter sales for AbbVie's blood cancer franchise soared 32.1% year over year. Imbruvica generated sales of $1.2 billion, a 20.6% increase over the prior-year period total. Venclexta is on track to reach blockbuster status with sales more than doubling in Q1 to $317 million.

Another blockbuster-to-be, immunology drug Skyrizi, raked in sales of $300 million after winning FDA approval in April 2019. Rinvoq, which was approved by the FDA in August 2019 for treating rheumatoid arthritis, made $86 million in Q1, up from $47 million in the previous quarter.

There's another component to AbbVie's plan for coping with the coming loss of exclusivity for Humira in the U.S. that's also critical -- the company's acquisition of Allergan (NYSE:AGN). AbbVie confirmed that it expects to close the transaction this month.

The company had already announced in March that it received final approval for the acquisition in Europe and that it had entered into a consent agreement with the U.S. Federal Trade Commission (FTC). The only news in AbbVie's Q1 update was that this consent decree was still subject to additional review and approval by the FTC's commissioners. However, AbbVie doesn't anticipate any roadblocks.

Assuming all goes as planned, AbbVie's next quarterly update will include sales from Allergan's blockbuster Botox franchise, fast-rising star Vraylar, and more. Humira will still be a major contributor to AbbVie, but after the second quarter, the immunology drug will no longer generate more than half of the company's total revenue.

With the COVID-19 pandemic wreaking havoc on the financial results for many companies, you might have expected that it would be one of the biggest stories in AbbVie's Q1 update. But it wasn't.

AbbVie actually benefited from the pandemic in Q1. The company stated that its revenue increased by 240 basis points because of stocking up related to the COVID-19 outbreak.

It just might benefit even more in the future. The drugmaker is evaluating Imbruvica in a phase 2 clinical study in treating COVID-19 patients. AbbVie is also working with global health authorities to determine if HIV drug Kaletra could be effective in treating COVID-19.

The big pharma stock could still be affected in the future to some extent by the pandemic, though. AbbVie acknowledged that there are uncertainties related to the COVID-19 outbreak. The company is assuming that stay-at-home orders will be gradually lifted beginning in May and that business will largely return to normal over the next few months for physicians' offices and hospitals. If those assumptions don't pan out, COVID-19 could be a much more important factor in AbbVie's quarterly updates later this year.

View post:
The 3 Most Important Things to Know About AbbVie's Q1 Update - Motley Fool

Immunology

How to tell the difference between coronavirus symptoms and plain old allergies – Holmes County Times Advertiser

Allergy symptoms are likely to increase during the next two to three weeks as pollen counts grow into the thousands, said Leonard Bielory, professor of medicine, allergy, immunology and ophthalmology at Hackensack Meridian School of Medicine.

This content is being provided for free as a public service to our readers during the coronavirus outbreak. Please support local journalism by subscribing to the Northwest Florida Daily News or the Panama City News Herald .

WOODLAND PARK, N.J. With coronavirus restrictions in place, interactions with nature might be limited to a quick walk through the neighborhood, but its not hard to notice spring has sprung bringing allergy season with it.

Allergy symptoms are likely to increase as pollen counts grow into the thousands, said Leonard Bielory, professor of medicine, allergy, immunology and ophthalmology at Hackensack Meridian School of Medicine.

That raises a new dilemma: Some allergy symptoms, such as coughing, mimic signs of COVID-19. So how can sufferers tell the difference?

MARCH 15, 2020: What does the coronavirus infection do inside your body?

The combination and severity of symptoms is telling.

Patients with asthma or allergies who cough and experience breathlessness can resolve their symptoms with inhalers or prescription medication, Bielory said.

But if a patient has COVID-19, those solutions wont work and the symptoms are likely to be far more extreme. Coronavirus patients can have severe difficulty breathing. That's why many admitted to hospitals need the assistance of ventilators, which move air in and out of the lungs mechanically.

People who develop viruses, including COVID-19, may experience an associated fever within 24 to 72 hours of infection, Bielory said.

Fever is a major differential, he said. You dont normally get fever with allergies.

COVID-19 patients may also develop gastrointestinal symptoms and muscle aches and pains, according to the Asthma and Allergy Foundation of America. Up to two-thirds of them may lose their sense of smell, Bielory said. None of those symptoms is associated with allergies.

Read the original post:
How to tell the difference between coronavirus symptoms and plain old allergies - Holmes County Times Advertiser

Immunology

COVID-19: T cells offer clues to the potential power of Roche’s Actemra – FierceBiotech

The successful activation of T cells is critical to the immune system's ability to clear infections. A new retrospective study from China found that COVID-19 patients had remarkably low T-cell counts in their blood. And they had sky-high levels ofsome pro-inflammatory cytokines such as IL-6which Roches Actemra targets.

Actemra has previously shown promise at controlling potentially life-threatening cytokine storm in COVID-19 patients in China and France, and Roche is running a large phase 3 to confirm its effectiveness in treating patients with COVID-19.

In thestudy from China, published in Frontiers in Immunology, a group of scientists analyzed T-cell counts in 499 COVID-19 patients being treated for the disease in the city of Wuhan. They found a negative correlation between T-cell numbers and cytokines. The team suggested that the novel coronavirus doesnt attack T cells directly, but rather triggers an overproduction of cytokines, which in turn contributes to the depletion and exhaustion of T cells.

FiercePharma Presents the Virtual eRegulatory Operations Summit

Join industry experts and learn how to build and manage cohesive, compliant, and timely electronic submissions through innovative technologies and seamless clinical documentation processes.

The Chinese researchers noticed that about 76% of patients had insufficient T cells, and the level was much lower in those in intensive care. They then examined the concentrations of cytokines from the blood of these patients and found that the levels of TNF-alpha, IL-6 and IL-10 were significantly increased in infected patients. The elevation was even more pronounced in ICU patients.TNF-alpha is known to promote T-cell death, and dysregulated IL-6 has been shown to induce chronic inflammation.

As the patients gradually recovered, their T cell counts improved, while levels of those cytokines dramatically declined. Sothe researchers hypothesize that the depletionof T cells in COVID-19 patients may be the result ofcytokines impedingT-cell survival or proliferation.

Whats more, the T cells that did survive showed signs of exhaustion, with markedly higher expression of immune-inhibitory factors such as PD-1 and Tim-3 on their surface. That was a sign that their functioning was impaired, the researchers reported.

Based on these findings, the team arguedthe secretion of pro-inflammatory cytokines likely does not come from T cells, butthat the cytokine storm may promote the death of the critical immune cells.

RELATED:Reviving tired T cells to improve immuno-oncology treatments

Finding new ways to restore the vigor of immune cells hasbeen of interest in the biomedical research community, notably in oncology. A team at the University of Pennsylvania, for example, found that a protein called TOX in T cells controls the balance of effector T cells and exhausted T cells, suggesting it could be targeted to improve immuno-oncology treatments. And scientists at the La Jolla institute for Immunology recently showed that crippling all three proteins of Nr4a transcription factors could rejuvenate exhausted CAR-T cells to fight solid tumors in mice.

Based on their findings, the Chinese team suggested thatfuture COVID-19 research should focus on identifying more drugs that provide much-needed support toT cells.

We should pay more attention to T cell counts and their function, rather than respiratory function of patients, the studys corresponding author, Yongwen Chenof the Third Military Medical University in China, said in a statement, adding that more urgent, early intervention may be required in patients with low T lymphocyte counts.

Go here to read the rest:
COVID-19: T cells offer clues to the potential power of Roche's Actemra - FierceBiotech

Immunology

COVID-19: blood plasma treatment tested at Guy’s and St Thomas’ – London SE1

A blood plasma treatment for COVID-19 is to be tested at Guy's and St Thomas' as part of a new trial.

The treatment known as 'convalescent plasma' is being tested as a treatment for patients who are severely ill with COVID-19 as part of the national priority trial REMAP-CAP. Supported by the National Institute for Health Research, REMAP-CAP is an international trial testing different treatments for patients who are severely ill with COVID-19.

The 'convalescent plasma' treatment involves blood plasma donations from patients who have recovered from COVID-19. This plasma is transfused into COVID-19 patients whose bodies are not producing enough of their own antibodies against the virus, in an attempt to support the patients fighting the disease.

The trial is co-led by Dr Manu Shankar-Hari, a consultant in intensive care medicine at Guy's and St Thomas', along with experts from NHS Blood and Transplant and the University of Cambridge.

The research lab run by Dr Shankar-Hari within the King's College London School of Immunology and Microbial Sciences is coordinating the underpinning science behind the convalescent plasma treatment.

Dr Shankar-Hari, who is also an NIHR Clinician Scientist and Reader and Consultant in Intensive Care Medicine at King's College London, said: "At the moment, there is no proven treatment for COVID-19. Convalescent plasma is a promising treatment that could help patients whose bodies aren't producing enough antibodies to curb the disease. This trial will help us understand whether the treatment should be used more widely to treat COVID-19.

"We are incredibly grateful to all the patients who are taking part in our COVID-19 trials and their families. At a difficult time for them, our patients are taking part in studies that will help us to understand more about how to treat the condition."

Read the original here:
COVID-19: blood plasma treatment tested at Guy's and St Thomas' - London SE1

Immunology

Coronavirus second wave panic as scientists admit they’re ‘flying blind’ over immunity – Express.co.uk

Danny Altmann, Professor of Immunology at Imperial College London, admitted scientists currently do not have any idea whether confirmed coronavirus patients will develop immunity from catching the virus for a second time.During a remote Commons Science and Technology Committee meeting, Professor Altmann also raised serious concerns about lifting the UK-wide lockdown without sufficient knowledge of the virus or a vaccine.

He said: Immunologists when they are studying live infection or vaccination get very obsessed with these things called quarrians of protection.

And that means all the tests you can do, all the measurable, give you a number to quantify whether the likelihood is this person would be protected next time they meet this bug.

So that is the thing we need to know we kind of don't know the foggiest notion of for this infection at the moment.

Britons have been living under restrictions since March 23 and Professor Altmann has cast serious doubt as to whether social distancing measures can be lifted without accurate anti-body testing and knowledge of exactly who is carrying the virus.

The medical expert is also adamant it would take at least another six months to gather enough evidence in order to fully understand the disease.

He said: "As an immunologist and knowing how desperately lethal this virus can be, I'd be very worried about any assumptions on those grounds - terribly worried.

"For a virus we've known about since January, it's been a very steep learning curve.

"Without really good antibody testing and seroprevalence in the population, we're flying blind.

"We haven't got a clue who's had it, how many have had it, where they've had it, or where we stand for the future for second waves.

READ MORE:Angela Merkel at risk of reimposing lockdown as infection rate spikes

Up to 1,102 participants will be recruited across multiple study sites in Oxford, Southampton, London and Bristol.

The Department for Health has confirmed a further 586 patients have died from COVID-19 in UK hospitals.

As of 5pm on Monday the total number of coronavirus fatalities now stands at 21,678.

See the original post:
Coronavirus second wave panic as scientists admit they're 'flying blind' over immunity - Express.co.uk

Immunology

How to tell the difference between coronavirus symptoms and allergies – USA TODAY

As flu season comes to an end and allergy season starts to heat up, there may be concerns about symptoms that mimic the new coronavirus COVID-19. Wochit

WOODLAND PARK, N.J. With coronavirus restrictions in place, interactions with nature might be limited to a quick walk through the neighborhood, but its not hard to notice spring has sprung bringing allergy season with it.

Allergy symptoms are likely to increase during the next two to three weeks as pollen counts grow into the thousands, said Leonard Bielory, professor of medicine, allergy, immunology and ophthalmology at Hackensack Meridian School of Medicine.

If it wasnt for the cold snap, wed be having an incredible amount of pollen right now, Bielory said Monday. Once it warms up, with the rain weve gotten, its going to be quite an intense opening season for trees. Its going to explode.

That raises a new dilemma:Some allergy symptoms, such as coughing, mimic signs of COVID-19. So how can sufferers tell the difference?

Coronavirus: These are the 6 new possible symptoms the CDC added to its list

Prevention: How to clean, reuse or hack a coronavirus mask

The combination and severity of symptoms is telling.

Patients with asthma or allergies who cough and experience breathlessness can resolve their symptoms with inhalers or prescription medication, Bielory said.

But if a patient has COVID-19, those solutions wont work and the symptoms are likely to be far more extreme. Coronavirus patients can have severe difficulty breathing. That's why many admitted to hospitals need the assistance of ventilators, which move air in and out of the lungs mechanically.

People who develop viruses, including COVID-19, may experience an associated fever within 24 to 72 hours of infection, Bielory said.

Fever is a major differential, he said. You dont normally get fever with allergies.

COVID-19 patients may also develop gastrointestinal symptoms and muscle aches and pains, according to theAsthma and Allergy Foundation of America. Up to two-thirds of them may lose their sense of smell, Bielory said. None of those symptoms is associated with allergies.

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/news/health/2020/04/30/coronavirus-symptoms-compared-allergies-fever-major-difference/3046394001/

Original post:
How to tell the difference between coronavirus symptoms and allergies - USA TODAY

Neuroscience

Insights on the Worldwide Neuroscience Antibodies and Assays Industry to 2024 – Key Drivers and Challenges – Yahoo Finance

Dublin, May 01, 2020 (GLOBE NEWSWIRE) -- The "Global Neuroscience Antibodies and Assays Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

The author has been monitoring the global neuroscience antibodies and assays market and it is poised to grow by USD 1.36 bn during 2020-2024, progressing at a CAGR of 8% during the forecast period. The reports on global neuroscience antibodies and assays market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by technological advances. In addition, advances in neuroscience instruments is anticipated to boost the growth of the global neuroscience antibodies and assays market as well.

Key Trends for global neuroscience antibodies and assays market growthThis study identifies advances in neuroscience instruments as the prime reasons driving the global neuroscience antibodies and assays market growth during the next few years.

Prominent vendors in global neuroscience antibodies and assays marketWe provide a detailed analysis of around 25 vendors operating in the global neuroscience antibodies and assays market, including some of the vendors such as Abcam Plc, Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., F. Hoffmann-La Roche Ltd., GenScript Biotech Corp., Merck KGaA, Rockland Immunochemicals Inc., Santa Cruz Biotechnology Inc., Tecan Group Ltd. and Thermo Fisher Scientific Inc.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Key Topics Covered:

1. EXECUTIVE SUMMARY2. SCOPE OF THE REPORT

3. MARKET LANDSCAPE

4. MARKET SIZING

5. FIVE FORCES ANALYSIS

6. MARKET SEGMENTATION BY PRODUCT

7. CUSTOMER LANDSCAPE

8. GEOGRAPHIC LANDSCAPE

9. DRIVERS AND CHALLENGES

10. MARKET TRENDS

11. VENDOR LANDSCAPE

12. VENDOR ANALYSIS

13. APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/olpv03

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read this article:
Insights on the Worldwide Neuroscience Antibodies and Assays Industry to 2024 - Key Drivers and Challenges - Yahoo Finance

Neuroscience

New Web and APP platform offers Neuroscience Sports Breakthrough Approach to Calisthenics and Body Workouts Training – Life Pulse Health

UNITED STATES 04-30-2020 (PRDistribution.com) Biomedical expert Jean Fallacara also known as the Cyborg has teamed up with elite coaches and professional athletes from CalisthenixPro Team to create a new unique web application platform that offers a new approach to calisthenics training. Calisthenics is a great form of exercise that involves a variety of movements carried out rhythmically with minimal equipment to exercise larger muscle groups. Recent research indicates that the exercise boosts the brainpower.

The new web application Cyborgainz combines neuroscience to increase the brains neuroplasticity, create and strengthen motor pathways faster. This often makes is easier and faster to master any skills. Individuals using the application will be offered custom workout and personalized plans that match each of the programs with an individuals specific goals and objectives.

Speaking about the platform, Jean Fallacara who has over 20 years experience in the science technology field emphasized the need to train the body and mind.

If the body is being trained, shouldnt athletes also train the brain? The difference between good athletes and great athletes is that great athlete knows the way to maximize strength and potential is to train mind and body.We created Cyborgainz for this purpose. Our platform helps you understand the neurobiological effects of your training helping you to be stronger, faster, quicker and more explosive like a Cyborg

The specific flexible workout programs on the platform have been designed by a team of calisthenics & freestyle experts to help the trainer decode any skill that they have been desiring to learn. Since each of the programs is custom built for every person, it also allows for important individual circumstances such as injuries or allergies. The testing activity of the different forms of brain stimulation including transcranial direct current stimulation (TDCS) is carried out on this application.

The meal plan created for the client consists of a 7 day diet plan and clients have a choice of the different meals they prefer. For instance, one can decide whether to have Italian or international cuisine or general, vegetarian or paleo diet. A shopping list will also be provided for the client as they strive towards achieving their body and mind goals. Exercises to be carried out are entered into the system together with other additional information such as the exercise level that is beginner, intermediate and advanced. The exercise description and instructions including a video on how to carry it out and another part for filling in injury information just in case.

The utilization of neuroscience in the sports is something that has been studied by neuroscientists for a long time. Neuroscience research has also revealed the differences between the brain activity of the top performers and the novices. According to research conducted on Neymar da Silva Santos, a top Brazilian player, the loading of working of the brain plays a major role in influencing the cognitive aspects during performance such as the ability to predict and detect the actions of other players in the case of the footballer.

By combining mind and body training, Cyborgainz to change the approach to calisthenics training and body building.

About Jean Fallacara

Born of a disruptive spirit and an imaginative mindset, Jean Fallacara has been working as an experienced executive focused on technology products for the science business. He has over 20 years of experience in this field where he has founded and led a number of science-technology companies. He is also an expert in strategic planning, operations, investment management, and marketing. His specialized skills in achieving strategic objectives with the primary focus on increasing shareholders wealth through merger, acquisition, new business developments, or undertaking share offering and raising capital has seen him work with a number of companies helping them to create meaningful relationships with their clients, partners and, the communities in which they operate. Currently, Jean Fallacara is the Founder CEO at Z-SCI Corporation headquartered in Westmount, Qc- Canada with US branches and manufacturing bases in South-Korea. The firm is an international company with a successful record of developing laboratory equipment for the biomedical market. To learn more about calisthenics, find him on his Instagram: @cyborggainz

Media Contacts:

Company Name: CyborgainzFull Name: Jean FallacaraPhone: Email Address: Send EmailWebsite: https://cyborggainz.com/

For the original news story, please visit https://prdistribution.com/news/new-web-and-app-platform-offers-neuroscience-sports-breakthrough-approach-to-calisthenics-and-body-workouts-training.html.

Powered by WPeMatico

Visit link:
New Web and APP platform offers Neuroscience Sports Breakthrough Approach to Calisthenics and Body Workouts Training - Life Pulse Health